Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Hepatic encephalopathy

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

New disorientation, drowsiness or coma in cirrhosis is an emergency because sepsis, gastrointestinal bleeding, hypoglycaemia, intracranial disease and sedative toxicity can coexist. Use an ABCDE assessment, check capillary glucose immediately, seek senior critical-care support for grade III–IV encephalopathy or an unsafe airway, and treat suspected infection or bleeding promptly. Do not delay resuscitation while waiting for ammonia, nor assume reduced consciousness is hepatic until dangerous alternatives have been assessed.

Synopsis

Recognise overt hepatic encephalopathy, protect the deteriorating patient, identify reversible precipitants, and prevent recurrence without mistaking a clinical syndrome for an ammonia result.

  • Hepatic encephalopathy is a clinical neuropsychiatric syndrome caused by liver insufficiency or portosystemic shunting after competing explanations have been considered.
  • Asterixis supports metabolic encephalopathy but is neither specific to liver disease nor reliably present in deep coma.
  • Search actively for infection, gastrointestinal bleeding, constipation, dehydration, acute kidney injury, electrolyte disturbance and medicines that depress cognition.
  • A venous ammonia concentration does not confirm, exclude or grade overt encephalopathy; a normal result should prompt diagnostic reconsideration.
  • Lactulose is titrated to regular soft stools, not profuse diarrhoea, because over-treatment can worsen dehydration, hypokalaemia and encephalopathy.
  • Rifaximin is used with specialist oversight to reduce recurrent overt episodes, commonly alongside lactulose, rather than to replace precipitant treatment.
  • Avoid routine protein restriction; provide adequate energy and protein with dietetic help because sarcopenia reduces extrahepatic ammonia handling.
  • Recurrent or persistent encephalopathy should trigger review of adherence, constipation, sedating medicines, large spontaneous shunts, TIPSS and transplant suitability.

Key red flags

Overt disorientation

Disorientation to time or place, inappropriate behaviour, lethargy and asterixis suggest overt encephalopathy, but fever, focal signs, head injury or meningism should redirect urgent investigation.

Threatened airway

Marked somnolence, absent protective reflexes, recurrent vomiting or coma creates aspiration risk. Escalate early for airway protection and monitored care rather than repeatedly giving oral treatments.

Neurological alternative

A focal deficit, unequal pupils, seizure, sudden severe headache, trauma or prolonged failure to improve is atypical and may justify urgent brain imaging or neurological review.

Investigation priorities

01
Bedside glucose and physiological observationsFirst step

Detect immediately reversible coma and quantify acute physiological compromise.

Management branches

StabiliseManage overt deterioration

A person with cirrhosis or portosystemic shunting develops new disorientation, somnolence or coma.

  1. Perform ABCDE assessment, check glucose, record Glasgow Coma Scale and West Haven features, obtain intravenous access, and call for senior help if airway protection is doubtful.
  2. Stop or withhold non-essential sedatives and nephrotoxic or volume-depleting medicines while assessing bleeding, sepsis, renal injury, electrolyte imbalance and recent alcohol or drug exposure.
  3. Start enteral lactulose when the airway and route are safe, using local guidance for an alternative route if swallowing is unsafe, while treating each identified precipitant in parallel.
  4. Escalate grade III–IV disease, shock, respiratory compromise, acute liver failure or failure to improve to critical care and the regional hepatology or transplant service.

Key medicines

Lactulose oral solutionInitially 30–45 mL three or four times daily for hepatic encephalopathy, then adjust to produce two or three soft stools daily; follow the current SmPC and local acute pathway.Protect the airway before oral administration. Excess dosing causes diarrhoea, dehydration, hypernatraemia or hypokalaemia; avoid in gastrointestinal obstruction or perforation and reassess abdominal distension or pain.
Rifaximin 550 mg tabletsTake 550 mg twice daily when prescribed by the specialist service to reduce recurrence of overt hepatic encephalopathy; review continued need and adherence according to the local pathway.It is not rescue monotherapy for coma or untreated precipitants. Check the current SmPC for hypersensitivity, severe skin reactions, C. difficile diarrhoea, warfarin INR effects and important P-glycoprotein interactions.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSG and BASL decompensated cirrhosis care bundleUK first-24-hour approach to precipitants, infection, bleeding, AKI and encephalopathy in decompensated cirrhosis.
  • NICE TA337 rifaximin recommendationsNational recommendation for rifaximin within its authorisation to reduce recurrence of overt hepatic encephalopathy.
  • Duphalac lactulose Summary of Product CharacteristicsLicensed hepatic-encephalopathy dosing, titration target, contraindications and adverse-effect information.
  • Targaxan rifaximin Summary of Product CharacteristicsCurrent UK rifaximin dose, indication, safety warnings and interaction information.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom